1.16 References 總表
指引（Guidelines）
ADA Standards of Care 2026 — Press Release
ADA SoC 2026 Section 2 — Diagnosis and Classification
ADA SoC 2026 Section 6 — Glycemic Goals & Hyperglycemic Crises (PubMed)
ADA SoC 2026 Section 9 — Pharmacologic Approaches
ADA SoC 2026 Section 13 — Older Adults
ADA SoC 2026 — Summary of Revisions
ADA Clinical Guidelines (Professional Hub)
AACE 2026 Algorithm for T2DM (PubMed)
AACE 2023 Comprehensive T2DM Algorithm
ADA/EASD 2022 Consensus Report
KDIGO 2024 CKD Guideline (PDF)
KDIGO Diabetes & CKD (Official)
KDIGO 2022 Diabetes in CKD Update (PubMed)
Taiwan DAROC 官方
Taiwan Diabetic Kidney Disease Guideline 2024
Taiwan Diabetes Lipid Guideline 2023 (DAROC)
DAROC 2018 Executive Summary (PubMed)
Landmark RCTs — GLP-1 RA / GIP-GLP1
LEADER (NEJM 2016)
SUSTAIN-6 (NEJM 2016)
REWIND (Lancet 2019)
SELECT (NEJM 2023)
FLOW (NEJM 2024)
SURPASS-2 (NEJM 2021)
SURMOUNT-1 (NEJM 2022)
SURMOUNT-5 (NEJM 2025)
Tirzepatide for Diabetes Prevention (NEJM 2024)
Landmark RCTs — SGLT2i
EMPA-REG OUTCOME (NEJM 2015)
CANVAS (NEJM 2017)
DECLARE-TIMI 58 (NEJM 2019)
DAPA-CKD (NEJM 2020)
EMPA-KIDNEY (NEJM 2023)
Long-term EMPA-KIDNEY (NEJM 2024)
DAPA-HF (NEJM 2019)
EMPEROR-Reduced (NEJM 2020)
EMPEROR-Preserved (NEJM 2021)
DELIVER (NEJM 2022)
Landmark RCTs — DKD / Other
FIDELIO-DKD (NEJM 2020)
FIGARO-DKD (NEJM 2021)
Landmark RCTs — T1DM
TN-10 Teplizumab Prevention (NEJM 2019)
PROTECT Teplizumab Newly Diagnosed (NEJM 2023)
台灣藥物資料查詢
食藥署西藥許可證查詢
中央健保署藥品代碼查詢
⚠️ 免責聲明：本整理為臨床知識複習用途，實際處方需依個別病人狀況、共病、藥物交互作用、健保給付狀態與最新指引調整，並由醫師判斷。商品名與健保給付以衛福部食藥署許可證與健保署公告為準。
